OPKO Health, Inc. (TLV:OPK)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 3.30B -12.6% |
| Revenue (ttm) | 1.83B -15.7% |
| Net Income | -672.24M |
| EPS | -0.87 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 530,703 |
| Open | 439.00 |
| Previous Close | 439.00 |
| Day's Range | 437.00 - 453.70 |
| 52-Week Range | 310.00 - 516.90 |
| Beta | 1.49 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 28, 2026 |
About OPKO Health
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune syst... [Read more]
Financial Performance
In 2025, OPKO Health's revenue was $606.88 million, a decrease of -14.90% compared to the previous year's $713.14 million. Losses were -$225.68 million, 324.0% more than in 2024.
Financial numbers in USD Financial StatementsNews
OPKO Health Transcript: AGM 2026
The meeting approved all board proposals, including director elections and the 2026 equity plan. Key business updates highlighted clinical pipeline progress, asset sales, and strong cash flow from royalties and diagnostics. $98 million remains authorized for share repurchases.
Entera Bio and Opko Health present preclinical data for oral peptides
Entera Bio (ENTX) and Opko Health (OPK) reported preclinical data at the ENDO 2026 annual meeting for their co-developed EB612 and EB618 oral peptide programs. For EB612, a long-acting oral…
Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026
MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) OPKO Biologics, an OPKO Health company, presented preclinical data for OPK8801001 at ENDO 2026, the Endocrine Society's annual ...
OPKO Health Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing a robust pipeline of multispecific antibodies and in vivo CAR T therapies, with key data updates expected for MDX-2001, the Merck EBV vaccine, and a SARS antibody program in the next 6-12 months. Global clinical expansion and strategic collaborations are driving innovation and growth.
OPKO Health Proxy statement: Proxy filing
OPKO Health filed a proxy statement on May 15, 2026, providing details for shareholder voting and corporate governance matters.
OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies
Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models Data will be presented at the American Society of Gene & Cell The...
OPKO Health Slides: Corporate presentation
OPKO Health has posted slides in relation to its latest quarterly earnings report, which was published on May 8, 2026.
OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
MIAMI, April 30, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) today announced that its subsidiary EirGen Pharma Limited (EirGen) has entered into an amendment to its agreement with ...
BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform
ELMWOOD PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- BioReference® Health LLC, an OPKO Health, Inc. company and a trusted provider of diagnostic testing in the United States, today announced the lau...
OPKO Health Proxy statement: Proxy filing
OPKO Health filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
OPKO Health Proxy statement: Proxy filing
OPKO Health filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Opko Health downgraded to Market Perform from Outperform at Barrington
Barrington analyst Michael Petusky downgraded Opko Health (OPK) to Market Perform from Outperform with no price target The firm previously had expected BRH break-even or profitability in 2026 and now…
OPKO Health Earnings Call Transcript: Q1 2026
Q1 2026 saw progress in clinical pipeline, improved operating losses, and strong cash reserves. Diagnostics and pharma segments showed sequential and year-over-year improvements, with guidance reaffirmed for 2026. Partnerships and streamlined operations support future growth.
OPKO Health Earnings release: Q1 2026
OPKO Health released its Q1 2026 earnings on April 28, 2026, summarizing the period's financial results.
OPKO Health Quarterly report: Q1 2026
OPKO Health has published its Q1 2026 quarterly earnings report on April 28, 2026.
OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first ...
OPKO Health's ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomas
OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026
MIAMI, April 21, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2026 after the close of the U.S. financia...
Opko Health price target lowered to $1.50 from $2.25 at Barrington
Barrington lowered the firm’s price target on Opko Health (OPK) to $1.50 from $2.25 and keeps an Outperform rating on the shares. The company reported a better than expected Q4…
OPKO Health to Participate in the Jefferies Biotech on the Beach Summit
MIAMI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Biotech on the Beach Summit, being held March 10-11, 202...
OPKO Health Earnings Call Transcript: Q4 2025
Q4 2025 revenue declined year-over-year due to asset sales, but diagnostics and pharma segments showed operational improvements, with 4Kscore and international sales driving growth. Strong cash position supports R&D and accelerated share repurchases.
OPKO Health Annual report: Q4 2025
OPKO Health has published its Q4 2025 annual report on February 26, 2026.
OPKO Health Earnings release: Q4 2025
OPKO Health released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results
MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces fi...
OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26
MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the U.S...